LAS VEGAS, July 18, 2014 /PRNewswire/ -- GrowBLOX
Sciences, Inc. (OTCQB: GBLX) a medical marijuana research and
development company, is applying for licenses to grow and dispense
in Illinois. The timing couldn't be better for GB Sciences
because Illinois State "lawmakers have
set final rules to allow medical marijuana in Illinois, opening the door for patients to
apply for ID cards this fall and to start purchasing legal cannabis
by next spring" as was reported in the Chicago Tribune on
Wednesday, July 16. The state intends
to approve a total of 21 licenses for cultivation and 60 for
dispensaries by September 2014.
CEO Craig Ellins explains, "Our
familiarity with state legal processes and experience in filing for
medical marijuana licenses in the state of Nevada, where we were granted a special use
permit for a dispensary and cultivation facility, puts us at an
advantage compared to the other local competitors filing for the
same licenses in Illinois."
The Company believes their GrowBLOX™ technology is a perfect fit
for the Illinois Medical Marijuana Market due to GB Sciences
ability to meet or exceed the strict quality standards being
imposed by the Illinois state
legislature. To this end, "the Illinois Department of Agriculture
is converting one of its labs into a testing center, where
marijuana can be checked for potency, mold and pesticides so
consumers know what they are getting," said Bob Morgan, coordinator of the state program as
was also reported in the Chicago Tribune on Wednesday, July 16.
Illinois' medical marijuana
market checks in at a purported 10,000 patients and will generate
anywhere from $25 million to $45
million in cannabis sales, according to The Marijuana
Business Factbook. The news of GB Sciences entrance into the
Illinois market comes just days
after The Company announced their entrance into the Florida Medical
Marijuana Market through its subsidiary GB Sciences Florida,
Inc.
About GB Sciences, Inc.
GrowBLOX Sciences, Inc., is a research and development company
that has proprietary indoor growing chambers specifically designed
for medical cannabis cultivation. The GrowBLOX™ chamber allows for
completely controlled growing conditions, ensuring the manufacture
of a consistent, toxin-free, natural and medicinal-grade product.
The Company believes that the advantages of a controlled
environment over traditional outdoor or greenhouse growing, will
empower the public, nutraceutical and pharmaceutical industries to
embrace cannabis as an effective treatment for a myriad of serious
medical conditions. http://www.gbsciences.com
Forward-Looking Statements
Except for historical information contained herein, the
statements in this release are forward-looking and made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are inherently
unreliable and actual results may differ materially. Examples
of forward-looking statements in this news release include
statements regarding the payment of dividends, marketing and
distribution plans, development activities and anticipated
operating results. Factors which could cause actual results to
differ materially from these forward-looking statements include
such factors as the Company's ability to accomplish its business
initiatives, significant fluctuations in marketing expenses and
ability to achieve and expand significant levels of revenues, or
recognize net income, from the sale of its products and services,
as well as the introduction of competing products, or management's
ability to attract and maintain qualified personnel necessary for
the development and commercialization of its planned products, and
other information that may be detailed from time to time in the
Company's filings with the United States Securities and Exchange
Commission. The Company undertakes no obligation to publicly update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
Contact:
Jonathan Barkman
Riverview Capital Enterprises
+1-866-845-0105
SOURCE GrowBLOX Sciences, Inc.